Galapagos NV - American Depositary Shares (GLPG)

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

The company expects to announce a new CFO “in the coming months.”

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.

Galapagos stock rises as EcoR1 Capital discloses a 9.9% stake and plans to engage on business and governance. Investor sees shares as deeply undervalued despite challenges, with new focus on CAR-T therapies under CEO Paul Stoffels.

The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.

FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.

GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets.

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG).

GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.